ANDROMEDA (NCT03201965) is an ongoing Phase 3, randomised, open-label study investigating the safety and efficacy of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone ...
Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...
DARZALEX ® SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...
SAN DIEGO — Final results of the phase 3 Andromeda study confirmed that adding daratumumab (DARA) — a human CD38-targeting monoclonal antibody — to bortezomib, cyclophosphamide, and dexamethasone (VCd ...
- Accelerated Approval of DARZALEX FASPRO®-based Combination Regimen Supported by the PHASE 3 ANDROMEDA Study Demonstrating a Significantly Higher Hematologic Complete Response Rate in this Rare and ...
Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results